Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589090 | 0.93 | POLB (0.35) | ABCG2ABCB1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3593530 | 0.87 | SIGMAR1 (0.33) | ABCG2ABCB1SIGMAR1KCNJ1ALDH1A1 | |
| SCHEMBL3593533 | 0.87 | SIGMAR1 (0.33) | ABCG2ABCB1SIGMAR1KCNJ1ALDH1A1 | |
| SCHEMBL3600917 | 0.87 | SIGMAR1 (0.33) | ABCG2ABCB1SIGMAR1KCNJ1ALDH1A1 | |
| SCHEMBL3604171 | 0.86 | ABCB1 (0.43) | ABCG2ABCB1ALDH1A1LMNA | |
| SCHEMBL13254291 | 0.84 | ALDH1A1 (0.32) | ABCG2ABCB1SIGMAR1KCNJ1ALDH1A1 | |
| SCHEMBL3602665 | 0.83 | PLA2G4A (0.38) | ABCG2ABCB1KCNJ1ALDH1A1LMNA | |
| SCHEMBL3599652 | 0.81 | MEN1 (0.38) | LMNA | |
| SCHEMBL3587922 | 0.80 | MAPK1 (0.37) | ABCB1SIGMAR1KCNJ1DRD3 | |
| SCHEMBL3592815 | 0.80 | KMT2A (0.36) | ABCB1KCNJ1ALDH1A1LMNADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | ABCG2 1850/4885ABCB1 2582/4885SIGMAR1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.